Aberrant TGF‐β activation and signaling can promote disease progression by stimulating epithelial–mesenchymal transition (EMT), angiogenesis, cancer‐associated fibroblast (CAF) activation, and immunosuppression within the tumor microenvironment (TME) [7, 8, 9]. Here, TGFB1 is linked to cancer.